A Second Space Age Spanning Omics, Platforms, and Medicine Across Orbits

Christopher E. Mason,James Green,Konstantinos I. Adamopoulos,Evan E. Afshin,Jordan J. Baechle,Mathias Basner,Susan M. Bailey,Luca Bielski,Josef Borg,Joseph Borg,Jared T. Broddrick,Marissa Burke,Andrés Caicedo,Verónica Castañeda,Subhamoy Chatterjee,Christopher Chin,George Church,Sylvain V. Costes,Iwijn De Vlaminck,Rajeev I. Desai,Raja Dhir,Juan Esteban Diaz,Sofia M. Etlin,Zachary Feinstein,David Furman,J. Sebastian Garcia-Medina,Francine Garrett-Bakelman,Stefania Giacomello,Anjali Gupta,Amira Hassanin,Nadia Houerbi,Iris Irby,Emilia Javorsky,Peter Jirak,Christopher W. Jones,Khaled Y. Kamal,Brian D. Kangas,Fathi Karouia,JangKeun Kim,Joo Hyun Kim,Ashley Kleinman,Try Lam,John M. Lawler,Jessica A. Lee,Charles L. Limoli,Alexander Lucaci,Matthew MacKay,J. Tyson McDonald,Ari M. Melnick,Cem Meydan,Jakub Mieczkowski,Masafumi Muratani,Deena Najjar,Mariam A. Othman,Eliah G. Overbey,Vera Paar,Jiwoon Park,Amber M. Paul,Adrian Perdyan,Jacqueline Proszynski,Robert J. Reynolds,April E. Ronca,Kate Rubins,Krista A. Ryon,Lauren M. Sanders,Patricia Savi Glowe,Yash Shevde,Michael A. Schmidt,Ryan T. Scott,Bader Shirah,Karolina Sienkiewicz,Maria Sierra,Keith Siew,Corey A. Theriot,Braden T. Tierney,Kasthuri Venkateswaran,Jeremy Wain Hirschberg,Stephen B. Walsh,Claire Walter,Daniel A. Winer,Min Yu,Luis Zea,Jaime Mateus,Afshin Beheshti

DOI: https://doi.org/10.1038/s41586-024-07586-8

IF: 64.8

2024-06-12

Nature

Abstract:The recent acceleration of commercial, private, and multi-national spaceflight has created an unprecedented level of activity in low Earth orbit (LEO), concomitant with the highest-ever number of crewed missions entering space and preparations for exploration-class (>1 year) missions. Such rapid advancement into space from many new companies, countries, and space-related entities has enabled a"Second Space Age." This new era is also poised to leverage, for the first time, modern tools and methods of molecular biology and precision medicine, thus enabling precision aerospace medicine for the crews. The applications of these biomedical technologies and algorithms are diverse, encompassing multi-omic, single-cell, and spatial biology tools to investigate human and microbial responses to spaceflight. Additionally, they extend to the development of new imaging techniques, real-time cognitive assessments, physiological monitoring, and personalized risk profiles tailored for astronauts. Furthermore, these technologies enable advancements in pharmacogenomics (PGx), as well as the identification of novel spaceflight biomarkers and the development of corresponding countermeasures. In this review, we highlight some of the recent biomedical research from the National Aeronautics and Space Administration (NASA), Japan Aerospace Exploration Agency (JAXA), European Space Agency (ESA), and other space agencies, and also detail the commercial spaceflight sector's (e.g. SpaceX, Blue Origin, Axiom, Sierra Space) entrance into aerospace medicine and space biology, the first aerospace medicine biobank, and the myriad upcoming missions that will utilize these tools to ensure a permanent human presence beyond LEO, venturing out to other planets and moons.

multidisciplinary sciences

What problem does this paper attempt to address?

The main issues this paper attempts to address are:

1. **Exploring the New Space Age**: With the acceleration of commercial, private, and multinational spaceflight activities, human activities in low Earth orbit (LEO) have reached unprecedented levels. The paper explores how this "second space age" can utilize modern molecular biology and precision medicine tools to provide precise aerospace medicine for astronauts.

2. **Application of Biomedical Technologies**: The paper details the application of these biomedical technologies in spaceflight, including multi-omics, single-cell, and spatial biology tools to study human and microbial responses to spaceflight. Additionally, it includes the development of new imaging technologies, real-time cognitive assessment, physiological monitoring, and personalized risk assessment.

3. **Pharmacogenomics and Biomarkers**: The paper also discusses how these technologies can advance pharmacogenomics (PGx), identify new spaceflight biomarkers, and develop corresponding countermeasures.

4. **Integrated Research and Data Sharing**: The paper emphasizes the research results from NASA, JAXA, ESA, and commercial spaceflight companies (such as SpaceX, Blue Origin, Axiom, Sierra Space), particularly the establishment of the first aerospace medical biobank and the upcoming various missions that will utilize these tools to ensure the long-term presence of humans beyond LEO, exploring other planets and moons.

5. **Cell and Tissue Responses**: The paper provides a detailed analysis of the effects of spaceflight on cells and tissues, including changes in the genome, transcriptome, chromatin structure, telomeres, immune system, and metabolic functions due to radiation exposure and microgravity. These studies help understand the specific impacts of the space environment on human health and provide guidance for future space missions.

6. **Personalized Medical Countermeasures**: Ultimately, the paper aims to create personalized medical countermeasures for astronauts through these studies, ensuring human safety during long-duration, high-risk, and high-radiation-level space missions.